- Title
- Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4
- Creators
- Tim N. Beck - Fox Chase Cancer CenterErica A. Golemis - Fox Chase Cancer CenterDaniel M. Geynisman - Fox Chase Cancer Center
- Publication Details
- European urology, v 70(3), pp E75-E76
- Publisher
- Elsevier
- Number of pages
- 2
- Grant note
- R21CA181287 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) R21 CA181287; P30 CA006927; F30 CA180607 / NCI NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Biochemistry and Molecular Biology
- Web of Science ID
- WOS:000380754000004
- Scopus ID
- 2-s2.0-84959289272
- Other Identifier
- 991019318932104721
Journal article
Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4
European urology, v 70(3), pp E75-E76
01 Sep 2016
PMID: 26947605
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Metrics
12 Record Views
Details
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Urology & Nephrology